Business Wire

Australian Department of Home Affairs’ New Biometric System Goes Live Using Unisys Stealth(identity)™ and IDEMIA Biometrics

3.6.2020 13:48:00 EEST | Business Wire | Press release

Share

Unisys Corporation (NYSE: UIS) and IDEMIA today announced that the Australian Department of Home Affairs’ new Enterprise Biometric Identification Services (EBIS) system has gone live. EBIS is based on the Unisys Stealth(identity)™ multi-factor identity management and authentication solution and, using IDEMIA’s facial and fingerprint recognition algorithms, is one of the world’s most accurate biometric identity management systems used for visa and border processing to secure Australia’s’ borders and facilitate the flow of legitimate travellers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005403/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

EBIS will be used by the department to match the facial images and fingerprints of people including those wishing to travel to Australia such as visa applicants and the facial images for citizenship applicants. The system simultaneously facilitates the processing of legitimate travellers and is designed to support anticipated growth in visa applications, border clearances and applications for citizenship over the next 10 years.

In 2019 there was a record annual 9.5 million visitors to Australia, 3.9 million more than 10 years earlier and 220 300 more than the previous year1. To facilitate travellers’ journeys, border clearance staff need to efficiently verify the identities of travellers and confirm they are who they say they are to prevent delays, avoid queues and improve the overall experience for travellers. In the future, EBIS will provide the capability to quickly flag people who may be crossing the border with fraudulent identities.

Unisys designed and implemented the system within 18 months of signing the contract with the department. EBIS is based on the Stealth(identity) multi-factor identity management and authentication solution, which supports face, finger, iris and voice recognition. It is a robust solution designed for high-volume (more than 100,000 transactions daily) and large-scale galleries (more than 100 million records). Stealth(identity) provides the core biometric identity management functionality of EBIS including the user interface, workflows, business rules, identity data and record linking and auditing functionality. EBIS replaces the previous biometrics matching system that was also provided and supported by Unisys for the last 12 years.

Rick Mayhew, vice president and general manager, Unisys Asia Pacific said: “The long term growth in the volume of travellers that will hopefully return after COVID-19, as well as the increased risk of potential terrorist or fraudulent activity, means that effective border security is more important than ever. EBIS provides Home Affairs with greater confidence in verifying an individual’s identity for efficient and early detection of criminals and persons of national security concern who change names and obtain passports using false identities. We have worked closely with the department and our partner IDEMIA, the global leader in Augmented Identity, to deliver one of the world’s leading solutions to help protect Australia’s borders and national assets.”

The core of EBIS’ fingerprint and facial biometric matching solution uses industry-leading biometric matching algorithms from IDEMIA to quickly and accurately match fingerprints and facial images.

IDEMIA’s flagship product Multi Biometric Search Services (MBSS) is a multi-biometric engine that uses face and fingerprint matching algorithms. This product combines high scalability (over 1 billion identities possible) with high availability, which is necessary for mission-critical systems, integrated within IDEMIA’s world-leading biometric algorithms. The product can also include other modalities such as iris recognition, where required.

Tim Ferris, President of IDEMIA Asia Pacific and Senior Vice President for Public Security and Identity, added: “We are thrilled to provide the biometric engine that powers the EBIS solution. This is the continuation of years of IDEMIA’s engagement in the Australian Borders ecosystem. The combined strengths of IDEMIA behind Unisys provide the Department of Home Affairs with a flagship platform to secure the border now and into the future.”

Unisys has extensive experience supporting government departments and agencies in Australia and around the world. More than 240 government agencies worldwide use Unisys solutions. For more information on Unisys' Public Sector solutions, visit http://www.unisys.com.au/industries/government/public-sector.

1 – Australian Bureau of Statistics -
https://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/3401.0Main%20Features13Mar%202020

About Unisys
Unisys is a global information technology company that builds high-performance, security-centric solutions for the most demanding businesses and governments. Unisys offerings include security software and services; digital transformation and workplace services; industry applications and services; and innovative software operating environments for high-intensity enterprise computing. For more information on how Unisys builds better outcomes securely for its clients across the Government, Financial Services and Commercial markets, visit www.unisys.com.au. Follow Unisys on Twitter and LinkedIn.

###

Unisys and other Unisys products and services mentioned herein, as well as their respective logos, are trademarks or registered trademarks of Unisys Corporation. Any other brand or product referenced herein is acknowledged to be a trademark or registered trademark of its respective holder.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Emily Nowland, The Impact Agency
+61 2 9519 5411 or +61 0413 942 179, emily@impactagency.com.au

Claire Hosegood, Unisys Asia Pacific
+61 411 253 663, claire.hosegood@au.unisys.com

Press

PR firm: Havas Paris
Hanna Sebbah
+33 (6) 63 73 30 30
idemia@havas.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release

The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye